Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Data for Roche's Evrysdi(R) -2-

07/29/2021 | 01:01am EDT

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com https://www.globenewswire.com/Tracker?data=19fRSZEqj9uUvXW_2IDM3mxw9tvZb9I8pL8hN3oNjHt9UndItIxYZR_BixBSD01mXqEWjVFTIQ82JfecEjrRIeV7xJRtCaRAv91-HeEC-gvfuC0QM8K3d6GtEIuwEvm1

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: +41 61 687 89 67     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
 
 
Roche Investor Relations 
Dr. Karl Mahler                        Jon Kaspar Bayard 
 Phone: +41 61 68-78503                 Phone: +41 61 68-83894 
 e-mail: karl.mahler@roche.com          e-mail: jon_kaspar.bayard@roche.com 
Dr. Sabine Borngräber             Dr. Bruno Eschli 
 Phone: +41 61 68-88027                 Phone: +41 61 68-75284 
 e-mail: sabine.borngraeber@roche.com   e-mail: bruno.eschli@roche.com 
Dr. Birgit Masjost                     Dr. Gerard Tobin 
 Phone: +41 61 68-84814                 Phone: +41 61 68-72942 
 e-mail: birgit.masjost@roche.com       e-mail: gerard.tobin@roche.com 
 
Investor Relations North America 
Loren Kalm 
 Phone: +1 650 225 3217 
 e-mail: kalm.loren@gene.com 
 

Attachment

   -- 29072021_MR_Evrysdi 
      https://ml-eu.globenewswire.com/Resource/Download/f5007654-ce12-4634-b6b0-5491164a5d7c 
 
 
 

(END) Dow Jones Newswires

July 29, 2021 01:00 ET (05:00 GMT)

All news about ROCHE HOLDING AG
01:23aROCHE : Rolls Out Three Respiratory Tests On Cobas 6800/8800 Systems
MT
01:00aPRESS RELEASE : Roche launches three respiratory -2-
DJ
01:00aROCHE : launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to..
AQ
01:00aPRESS RELEASE : Roche launches three respiratory test panels on cobas 6800/8800 Systems in..
DJ
09/21ROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-Stage Lun..
AQ
09/20ROCHE : Booster programme welcome but plans must be in place for boosters for all vaccinat..
AQ
09/20ROCHE : Says Phase III Trial of Tecentriq Showed Reduction in Lung Cancer Recurrence, Deat..
MT
09/20ROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-stage Lun..
BU
09/20ROCHE : New Phase III data support the benefit of Roche's Tecentriq in early-stage lung ca..
AQ
09/20PRESS RELEASE : New Phase III data support the -2-
DJ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 435 M 66 564 M 66 564 M
Net income 2021 14 639 M 15 861 M 15 861 M
Net cash 2021 4 891 M 5 299 M 5 299 M
P/E ratio 2021 19,4x
Yield 2021 2,77%
Capitalization 297 B 322 B 322 B
EV / Sales 2021 4,76x
EV / Sales 2022 4,62x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 339,35 CHF
Average target price 384,23 CHF
Spread / Average Target 13,2%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG9.82%321 584
JOHNSON & JOHNSON4.54%433 122
PFIZER, INC.20.08%246 246
NOVO NORDISK A/S52.07%234 070
ELI LILLY AND COMPANY36.32%208 668
ABBVIE INC.0.00%189 353